Saturday 17 October 2026
Export NMAD’s income statement to Excel — free account
Nomad Power Solutions, Inc.
NMAD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 44.8% and free cash flow fell 230.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
3.88
0.21
−5.13%
Follow NMAD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
10.42 | 3.88 | 2.78 | 12.87 |
Net Debt/EBITDA |
1.60 | 2.80 | 1.64 | 5.39 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.46 | 0.42 | 0.94 | 0.74 | |
Capex/Depreciation |
0.00 | 0.00 | — | — | |
Interest Coverage |
(3,602.80) | (480.13) | (641.10) | (2,611.00) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.58) | (0.22) | (0.17) | (0.12) | |
Cash per Share |
0.47 | 1.06 | 0.30 | 0.94 | |
Shareholders Equity per Share |
0.80 | 2.26 | 0.84 | 1.85 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.80 | 2.26 | 0.84 | 1.85 | |
Free Cash Flow |
(3.56) | (1.09) | (1.83) | (1.61) | |
Working Capital |
4.91 | 3.85 | 2.18 | 17.80 | |
Capital Expenditures |
(2.64) | 0.00 | — | — | |
Net Current Asset Value |
4.91 | 3.41 | 1.72 | 17.64 | |
| Other line items | |||||
Quick Ratio |
5.54 | 3.83 | 2.65 | 8.45 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.15) | (0.22) | (0.17) | (0.12) | |
Capex per Share |
(0.43) | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.15 | 0.26 | 0.25 | 0.21 | |
Average Assets |
3.56 | 6.94 | 6.19 | 13.92 | |
Average Common Equity |
0.11 | 3.28 | 3.42 | 12.82 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates